Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Payables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Payables for 8 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 2.43% to $44.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.0 million, a 2.43% increase, with the full-year FY2025 number at $40.1 million, changed N/A from a year prior.
  • Payables was $44.0 million for Q4 2025 at Outlook Therapeutics, up from $40.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $44.0 million in Q4 2025 to a low of $19.8 million in Q1 2025.